-$0.08 EPS Expected for Cytosorbents Corporation (CTSO) This Quarter
Equities analysts expect Cytosorbents Corporation (NASDAQ:CTSO) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Cytosorbents Corporation’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.05). Cytosorbents Corporation posted earnings of ($0.11) per share during the same quarter last year, which would suggest a positive year over year growth rate of 27.3%. The company is scheduled to report its next earnings report on Monday, November 6th.
According to Zacks, analysts expect that Cytosorbents Corporation will report full-year earnings of ($0.29) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.24). For the next financial year, analysts anticipate that the business will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.52) to ($0.27). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Cytosorbents Corporation.
Cytosorbents Corporation (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%.
A number of equities analysts recently issued reports on CTSO shares. Maxim Group set a $10.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a report on Monday, July 17th. ValuEngine upgraded Cytosorbents Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. B. Riley restated a “buy” rating and issued a $11.25 target price on shares of Cytosorbents Corporation in a report on Wednesday, August 2nd. HC Wainwright set a $13.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, Aegis restated a “buy” rating and issued a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $10.45.
Cytosorbents Corporation (NASDAQ CTSO) traded down 3.25% during mid-day trading on Wednesday, hitting $5.95. The company had a trading volume of 105,918 shares. Cytosorbents Corporation has a one year low of $3.30 and a one year high of $6.70. The company’s 50 day moving average price is $5.93 and its 200-day moving average price is $4.98. The company’s market cap is $167.39 million.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fortaleza Asset Management Inc. grew its holdings in shares of Cytosorbents Corporation by 81.6% in the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after acquiring an additional 10,500 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Cytosorbents Corporation by 145.2% during the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares in the last quarter. Finally, Skylands Capital LLC grew its holdings in shares of Cytosorbents Corporation by 87.7% during the second quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock valued at $2,555,000 after buying an additional 277,650 shares in the last quarter. Institutional investors and hedge funds own 6.53% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/01/0-08-eps-expected-for-cytosorbents-corporation-ctso-this-quarter.html.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.